Tscan therapeutics announces upcoming poster presentations at the 37th society for immunotherapy of cancer annual meeting

Waltham, mass., oct. 05, 2022 (globe newswire) -- tscan therapeutics, inc. (nasdaq: tcrx), a clinical-stage biopharmaceutical company focused on the development of t cell receptor (tcr) engineered t cell therapies (tcr-t) for the treatment of patients with cancer, today announced the acceptance of two abstracts at the upcoming society for immunotherapy of cancer (sitc) 37th annual meeting, being held from november 8–12, 2022, at the boston convention and exhibition center in boston, ma.
TCRX Ratings Summary
TCRX Quant Ranking